DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
DURECT Corporation (Nasdaq: DRRX) has announced its Q2 2025 financial results and provided an update on its proposed acquisition by Bausch Health. Under the merger agreement, Bausch Health will acquire DURECT for $1.75 per share in an all-cash transaction, representing approximately $63 million upfront, plus potential milestone payments of up to $350 million based on net sales achievements.
The transaction is expected to close in Q3 2025, with Bausch Health Americas initiating a tender offer for all outstanding DURECT shares on August 12, 2025. For Q2 2025, DURECT reported total revenues of $447,000 and a net loss of $2.3 million, compared to revenues of $646,000 and a net loss of $3.7 million in Q2 2024. The company's cash position stood at $6.7 million as of June 30, 2025, down from $12.0 million at the end of 2024.
DURECT Corporation (Nasdaq: DRRX) ha comunicato i risultati finanziari del secondo trimestre 2025 e ha fornito un aggiornamento sulla proposta di acquisizione da parte di Bausch Health. Con l'accordo di fusione, Bausch Health acquisirà DURECT a $1.75 per azione in un'operazione interamente in contanti, pari a circa $63 milioni iniziali, più possibili pagamenti legati a milestone fino a $350 milioni in base ai volumi di vendita netti.
La transazione è prevista per il terzo trimestre 2025, con Bausch Health Americas che avvierà un'offerta pubblica di acquisto per tutte le azioni in circolazione di DURECT il 12 agosto 2025. Nel secondo trimestre 2025 DURECT ha registrato ricavi totali di $447,000 e una perdita netta di $2,3 milioni, rispetto a ricavi di $646,000 e una perdita netta di $3,7 milioni nel Q2 2024. La liquidità della società era di $6,7 milioni al 30 giugno 2025, in calo rispetto a $12,0 milioni alla fine del 2024.
DURECT Corporation (Nasdaq: DRRX) ha anunciado sus resultados financieros del segundo trimestre de 2025 y dio una actualización sobre su propuesta de adquisición por parte de Bausch Health. Según el acuerdo de fusión, Bausch Health adquirirá DURECT por $1.75 por acción en una operación totalmente en efectivo, lo que representa aproximadamente $63 millones iniciales, más posibles pagos por hitos de hasta $350 millones en función de las ventas netas.
Se espera que la transacción se cierre en el tercer trimestre de 2025, y Bausch Health Americas iniciará una oferta pública de adquisición por todas las acciones en circulación de DURECT el 12 de agosto de 2025. En el segundo trimestre de 2025, DURECT registró ingresos totales de $447.000 y una pérdida neta de $2,3 millones, frente a ingresos de $646.000 y una pérdida neta de $3,7 millones en el Q2 de 2024. La posición de caja de la compañía era de $6,7 millones al 30 de junio de 2025, frente a $12,0 millones al cierre de 2024.
DURECT Corporation (Nasdaq: DRRX)는 2025년 2분기 재무 실적을 발표하고 Bausch Health의 인수 제안에 대한 최신 정보를 제공했습니다. 합병 계약에 따라 Bausch Health는 현금 거래로 주당 $1.75에 DURECT를 인수하며, 이는 약 $63 million의 선지급금과 순매출 실적에 따라 최대 $350 million의 마일스톤 지급 가능성을 포함합니다.
거래는 2025년 3분기에 완료될 예정이며, Bausch Health Americas는 2025년 8월 12일에 모든 DURECT 발행 주식에 대한 공개 매수를 시작할 예정입니다. 2025년 2분기 DURECT는 총수익 $447,000과 순손실 $2.3 million을 기록했으며, 이는 2024년 2분기의 수익 $646,000 및 순손실 $3.7 million과 비교됩니다. 회사의 현금 보유액은 2025년 6월 30일 기준 $6.7 million으로, 2024년 말의 $12.0 million에서 감소했습니다.
DURECT Corporation (Nasdaq: DRRX) a annoncé ses résultats financiers du second trimestre 2025 et a fait le point sur sa proposition d'acquisition par Bausch Health. Aux termes de l'accord de fusion, Bausch Health acquiert DURECT pour 1,75 $ par action dans le cadre d'une opération entièrement en numéraire, soit environ 63 M$ versés d'emblée, plus des paiements de jalons potentiels allant jusqu'à 350 M$ en fonction des ventes nettes.
La transaction devrait se finaliser au T3 2025, Bausch Health Americas lançant une offre publique d'achat pour l'ensemble des actions DURECT en circulation le 12 août 2025. Pour le second trimestre 2025, DURECT a déclaré des revenus totaux de 447 000 $ et une perte nette de 2,3 M$, contre des revenus de 646 000 $ et une perte nette de 3,7 M$ au T2 2024. La trésorerie s'élevait à 6,7 M$ au 30 juin 2025, en baisse par rapport à 12,0 M$ fin 2024.
DURECT Corporation (Nasdaq: DRRX) hat die Finanzergebnisse für das 2. Quartal 2025 veröffentlicht und ein Update zu dem vorgeschlagenen Erwerb durch Bausch Health gegeben. Nach dem Fusionsvertrag wird Bausch Health DURECT in einer Bartransaktion für $1,75 pro Aktie übernehmen, was etwa $63 Millionen an Vorauszahlungen entspricht, zuzüglich möglicher Meilensteinzahlungen von bis zu $350 Millionen abhängig vom Nettoumsatz.
Der Abschluss der Transaktion wird für das 3. Quartal 2025 erwartet; Bausch Health Americas wird am 12. August 2025 ein Übernahmeangebot für alle ausstehenden DURECT-Aktien einleiten. Im 2. Quartal 2025 meldete DURECT Umsatzerlöse von $447.000 und einen Nettoverlust von $2,3 Millionen, verglichen mit Umsatzerlösen von $646.000 und einem Nettoverlust von $3,7 Millionen im 2. Quartal 2024. Die liquiden Mittel des Unternehmens beliefen sich zum 30. Juni 2025 auf $6,7 Millionen, gegenüber $12,0 Millionen Ende 2024.
- All-cash acquisition offer at $1.75 per share, providing immediate value to shareholders
- Potential for additional milestone payments up to $350 million based on sales performance
- Net loss decreased by 37.8% year-over-year from $3.7M to $2.3M in Q2 2025
- Revenue declined 30.8% year-over-year from $646,000 to $447,000 in Q2 2025
- Cash position decreased 44.2% from $12.0M to $6.7M since December 2024
Insights
Bausch Health's acquisition of DURECT for $1.75/share plus milestone payments addresses DURECT's dwindling cash position while betting on larsucosterol's commercial potential.
The $1.75 per share acquisition price represents an all-cash transaction valued at approximately
The acquisition timing appears strategic when examining DURECT's financial position. With cash reserves declining from
For DURECT shareholders, the deal provides immediate liquidity and eliminates the risk of dilution from potential future fundraising efforts. The milestone structure enables them to participate in larsucosterol's potential success without bearing development and commercialization risks. For Bausch Health, the transaction aligns with its specialty pharmaceutical focus while offering a capital-efficient structure that back-loads payment contingent on commercial success.
The tender offer mechanism, rather than a shareholder vote, suggests confidence in shareholder acceptance and expedites the closing timeline, with completion expected within the current quarter.
Bausch Health will pay
Transaction expected to close in the third quarter of 2025
Recent business highlights and updates:
- In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with Bausch Health Americas, Inc. (Bausch Health Americas), a wholly owned subsidiary of Bausch Health and BHC Lyon Merger Sub, Inc. (Merger Sub), with DURECT surviving as a direct or indirect wholly owned subsidiary of Bausch Health (Merger Agreement).Under the terms of the Merger Agreement, Bausch Health will pay
per share of DURECT common stock in an all-cash transaction for an upfront consideration of approximately$1.75 at closing, with the potential for two additional net sales milestone payments of up to$63 million in the aggregate (subject to certain adjustments) if the milestone is achieved before the earlier of the 10 year anniversary of the first commercial sale of larsucosterol in$350 million the United States and December 31, 2045. The Merger is expected to be completed in the third quarter of 2025. Pursuant to the terms and conditions of the Merger Agreement, Merger Sub commenced on August 12, 2025 a tender offer to acquire all of DURECT's outstanding shares of common stock (the Tender Offer). As soon as practicable following the consummation of the Tender Offer and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into DURECT.
Financial Highlights for the First Quarter 2025:
- Total revenues were
and net loss was$447,000 for the three months ended June 30, 2025 compared to total revenues of$2.3 million and net loss of$646,000 for the three months ended June 30, 2024.$3.7 million - As of June 30, 2025, cash, cash equivalents and investments were
, compared to cash, cash equivalents and investments of$6.7 million at December 31, 2024.$12.0 million
Additional Information and Where to Find It
This communication is not an offer to buy nor a solicitation of an offer to sell any securities of DURECT. The solicitation and the offer to buy shares of DURECT's common stock is being made pursuant to a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials, that were filed by Bausch Health and Merger Sub with the SEC on August 12, 2025. In addition, DURECT has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Tender Offer with the SEC on August 12, 2025. The Tender Offer materials and the Solicitation/Recommendation statement, as they may be amended from time to time, contain important information that should be read carefully when they become available and considered before any decision is made with respect to the Tender Offer. Investors will be able to obtain a free copy of these materials and other documents filed by Bausch Health, Merger Sub and DURECT with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, copies of these materials and other documents by calling D.F. King & Co., the information agent for the Tender Offer, toll-free at (800) 628-8528 for stockholders or by calling collect at (212) 596-7578 for banks or brokers.
INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 OF DURECT AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.
About DURECT Corporation
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH has also been explored. For more information about DURECT, please visit www.durect.com and follow us on X (formerly Twitter) at https://x.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release contains statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would," or similar expressions are intended to identify forward-looking statements. The forward-looking statements are based on current beliefs and expectations and include, but are not limited to statements regarding beliefs about the potential benefits of the transaction; the considerations taken into account and the determination by the DURECT board of directors in approving the transaction; the planned completion and timing of the transactions contemplated by the Merger Agreement; and the prospective performance and outlook of the surviving company's business, performance, and opportunities. Actual results may differ materially from those contained in the forward-looking statements contained in this communication, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, uncertainties as to the timing and completion of the Offer and the Merger; uncertainties as to the percentage of DURECT stockholders tendering their Company Shares in the Offer; the possibility that competing offers will be made; the possibility that various closing conditions for the Offer or the Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable regulatory and/or governmental entities (or any conditions, limitations or restrictions placed on such approvals); risks relating to DURECT's liquidity during the pendency of the Offer and the Merger or in the event of a termination of the Merger Agreement; the risk that the Milestone Payments are not achieved; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, partners, vendors and other business partners; risks related to diverting management's attention from DURECT's ongoing business operations; the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, and other risks and uncertainties pertaining to DURECT's business, including the risks and uncertainties detailed in DURECT's public periodic filings with the SEC, as well as the Offer materials to be filed by Bausch Health Americas and Merger Sub and the Solicitation/Recommendation Statement on Schedule 14D-9 to be filed by DURECT in connection with the Offer.
Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law.. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission filings, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended June 30, 2025, when filed, under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.
NOTE: Larsucosterol is an investigational drug candidate under development and has not been approved for commercialization by the
DURECT CORPORATION CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts) (Unaudited) | ||||||||||||||||
Three months ended | Six months ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Collaborative research and development and other revenue | $ | 428 | $ | 606 | $ | 749 | $ | 1,102 | ||||||||
Product revenue | 19 | 40 | 19 | 40 | ||||||||||||
Total revenues | 447 | 646 | 768 | 1,142 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of product revenues | 7 | 27 | 7 | 29 | ||||||||||||
Research and development | 1,176 | 2,247 | 3,059 | 6,366 | ||||||||||||
Selling, general and administrative | 2,067 | 2,566 | 4,644 | 5,246 | ||||||||||||
Total operating expenses | 3,250 | 4,840 | 7,710 | 11,641 | ||||||||||||
Loss from operations | (2,803) | (4,194) | (6,942) | (10,499) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest and other income | 93 | 227 | 188 | 548 | ||||||||||||
Change in fair value of warrant liabilities | 445 | (78) | 326 | (1,796) | ||||||||||||
Other income (expense), net | 538 | 149 | 514 | (1,248) | ||||||||||||
Loss from continuing operations | (2,265) | (4,045) | (6,428) | (11,747) | ||||||||||||
Income (loss) from discontinued operations | — | 345 | (69) | 404 | ||||||||||||
Net loss | (2,265) | (3,700) | (6,497) | (11,343) | ||||||||||||
Net change in unrealized loss on available-for-sale securities, net | — | 3 | — | 7 | ||||||||||||
Total comprehensive loss | $ | (2,265) | $ | (3,697) | $ | (6,497) | $ | (11,336) | ||||||||
Net loss per share, basic | ||||||||||||||||
Loss from continuing operations | $ | (0.07) | $ | (0.13) | $ | (0.21) | $ | (0.38) | ||||||||
Income (loss) from discontinued operations | $ | — | $ | 0.01 | $ | — | $ | 0.01 | ||||||||
Net loss per common share | $ | (0.07) | $ | (0.12) | $ | (0.21) | $ | (0.37) | ||||||||
Net loss per share, diluted | ||||||||||||||||
Loss from continuing operations | $ | (0.07) | $ | (0.13) | $ | (0.21) | $ | (0.38) | ||||||||
Income (loss) from discontinued operations | $ | — | $ | 0.01 | $ | — | $ | 0.01 | ||||||||
Net loss per common share | $ | (0.07) | $ | (0.12) | $ | (0.21) | $ | (0.37) | ||||||||
Weighted-average shares used in computing net loss per share | ||||||||||||||||
Basic | 31,042 | 31,038 | 31,042 | 30,838 | ||||||||||||
Diluted | 31,163 | 31,038 | 31,042 | 30,838 |
DURECT CORPORATION CONDENSED BALANCE SHEETS (in thousands) (unaudited) | ||||||||
As of | As of | |||||||
June 30, 2025 | December 31, 2024 (1) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 6,502 | $ | 11,011 | ||||
Short-term Investments | — | 792 | ||||||
Accounts receivable, net | 511 | 453 | ||||||
Inventories, net | 291 | 106 | ||||||
Prepaid expenses and other current assets | 468 | 813 | ||||||
Total current assets | 7,772 | 13,175 | ||||||
Property and equipment, net | 29 | 41 | ||||||
Operating lease right-of-use assets | 1,683 | 2,135 | ||||||
Goodwill | 2,725 | 2,725 | ||||||
Long-term restricted investments | 150 | 150 | ||||||
Other long-term assets | 123 | 123 | ||||||
Total assets | $ | 12,482 | $ | 18,349 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 393 | $ | 309 | ||||
Accrued liabilities | 4,860 | 4,771 | ||||||
Deferred revenue, current portion | 320 | — | ||||||
Operating lease liabilities, current portion | 1,098 | 1,082 | ||||||
Warrant liabilities | 1,222 | 1,548 | ||||||
Total current liabilities | 7,893 | 7,710 | ||||||
Operating lease liabilities, non-current portion | 652 | 1,124 | ||||||
Other long-term liabilities | 454 | 384 | ||||||
Stockholders' equity | 3,483 | 9,131 | ||||||
Total liabilities and stockholders' equity | $ | 12,482 | $ | 18,349 |
(1) Derived from audited financial statements. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-reports-second-quarter-2025-financial-results-and-provides-update-on-proposed-acquisition-by-bausch-health-302528122.html
SOURCE DURECT Corporation